MULTIMAC: MonoMax for Abdominal Wall Closure

Sponsor
Aesculap AG (Industry)
Overall Status
Completed
CT.gov ID
NCT01901068
Collaborator
B.Braun Surgical SA (Industry)
200
3
33.9
66.7
2

Study Details

Study Description

Brief Summary

A great number of different suture techniques and suture materials are in use in order to reconstitute the abdominal wall integrity, but there is no surgical gold standard for abdominal wall closure until today. Various Meta-Analyses and randomized controlled trials have been performed, which compared non-absorbable or long-term absorbable versus rapid absorbable suture materials or monofilament versus multifilament suture materials, or continuous versus interrupted suture techniques respectively. This lack of evidence has the following outcome: burst abdomen is observed in 1-3% of patients within the first days after a laparotomy. The incidence of abdominal wall hernias 12 months postoperatively is estimated to be up to 20% (range 9 to 20%) . Wound infections develop in 3 to 21% of patients undergoing a median laparotomy within the first 30 days. At present most surgeons favour monofilament long-absorbable continuous sutures as the most suitable material for closing abdominal wounds after midline laparotomy.

Condition or Disease Intervention/Treatment Phase
  • Device: MonoMax

Study Design

Study Type:
Observational
Actual Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Multicentre, International, Prospective Post-market Clinical Follow-up to Evaluate MonoMax for Abdominal Wall Closure
Study Start Date :
Feb 1, 2013
Actual Primary Completion Date :
Sep 1, 2015
Actual Study Completion Date :
Dec 1, 2015

Arms and Interventions

Arm Intervention/Treatment
MonoMax

Elective primary laparotomy

Device: MonoMax
Abdominal wall will be closed with MonoMax after an elective primary laparotomy.

Outcome Measures

Primary Outcome Measures

  1. Frequency of reoperation due to burst abdomen [participants will be followed for the duration of hospital stay, an expected average of 10 days]

  2. Frequency of wound infections [participants will be followed for the duration of hospital stay, an expected average of 10 days]

Secondary Outcome Measures

  1. Incidence of wound healing until day of discharge [participants will be followed for the duration of hospital stay, an expected average of 10 days]

  2. Length of hospital stay [participants will be followed for the duration of hospital stay, an expected average of 10 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 18 years and older

  • Elective primary laparotomy

  • Written informed consent

Exclusion Criteria:
  • Peritonitis

  • Emergency surgery

  • Severe psychiatric and neurologic disease

  • Drug- and / or alcohol abuse according to local standard

  • Lack of informed consent

  • Current immunosuppressive therapy

  • Chemotherapy within the 2 weeks before operation

  • Radiotherapy of the abdomen completed less than 8 before surgery

  • Pregnant or breast-feeding women

  • Coagulopathy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Chirurgicka klinika, Fakultni nemocnine Hradec Kralove Czech Republic 500 05
2 Chirurgicka klinika, Fakultni nemocnine Olomouc Czech Republic 77520
3 Central Emergency Military Hospital Bucharest Romania

Sponsors and Collaborators

  • Aesculap AG
  • B.Braun Surgical SA

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Aesculap AG
ClinicalTrials.gov Identifier:
NCT01901068
Other Study ID Numbers:
  • AAG-O-H-1010
First Posted:
Jul 17, 2013
Last Update Posted:
Feb 10, 2016
Last Verified:
Feb 1, 2016
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by Aesculap AG

Study Results

No Results Posted as of Feb 10, 2016